AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6%

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6%
Thu, 8 Aug

AUROBINDO PHARMA has announced its results for the quarter ended June 2019. Here is a detailed performance review of the same:

AUROBINDO PHARMA Quarterly Financials

No. of Mths
Qtr. Ending
3
Jun-18*
3
Mar-19*
3
Jun-19*
QoQ ChangeYoY Change
Net SalesRs m42,50352,92254,4462.9%28.1%
Other incomeRs m437323158-51.1%-63.9%
TurnoverRs m42,94053,24554,6042.6%27.2%
ExpensesRs m35,39242,34742,9821.5%21.4%
Gross profitRs m7,11110,21511,33711.0%59.4%
DepreciationRs m1,5451,8662,40929.1%55.9%
InterestRs m295501499-0.4%68.9%
Profit before taxRs m5,7078,1708,5875.1%50.5%
TaxRs m1,1552,3112,278-1.5%97.1%
Profit after taxRs m4,5525,8596,3107.7%38.6%
Gross profit margin%16.719.320.8
Effective tax rate%20.228.326.5
Net profit margin%10.611.011.6
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster


Year-on-Year Performance:
  • The company's operating income during the quarter grew 28.1% on a year-on-year (YoY) basis. The expenses were up by 21.4% YoY during the same period.
  • The company's operating profit increased by 59.4% YoY during the quarter. Consequently, operating profit margins witnessed a growth and stood at 20.8% in 1QFY20 as against 16.7% in 1QFY19.
  • Depreciation charges increased by 55.9% and finance costs increased by 68.9% YoY, respectively.
  • Other income declined by 63.9% YoY during the quarter.
  • Net profit for the quarter increased by 38.6% YoY. Net profit margins during the quarter increased from 10.6% in 1QFY19 to 11.6% in 1QFY20.
Quarter-on-Quarter Performance:
  • The company's operating income during the quarter grew 2.9% on a quarter-on-quarter (QoQ) basis. The expenses were up by 1.5% QoQ during the same period.
  • The company's operating profit increased by 11.0% QoQ during the quarter. Consequently, operating profit margins witnessed a growth and stood at 20.8% in 1QFY20 as against 19.3% in 4QFY19.
  • Net profit for the quarter increased by 7.7% QoQ, while net profit margins increased from 11.0% in 4QFY19 to 11.6% in 1QFY20.

To see how AUROBINDO PHARMA has performed over the last eight quarters,please visit here.

AUROBINDO PHARMA Share Price Performance

Over the last one year,AUROBINDO PHARMA share price has moved down from Rs 611.4 to Rs 591.3, registering a Loss of Rs 20.1 or around 3.3%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 12,627.5 (up 0.5%). Over the last one year it has moved down from 14,502.8 to 12,627.5, a gain of 1,875 points (down 12.9%).

Overall, the S&P BSE SENSEX is down 1.4% over the year.

Current Valuations

At the current price of Rs 591.3, the price to earnings (P/E) ratio of AUROBINDO PHARMA stands at 13.6 times its trailing twelve months earnings, while its price to book value (P/BV) ratio stands at 3.0 times.

Equitymaster requests your view! Post a comment on "AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6%". Click here!

  

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Nov 6, 2019 | Updated on Nov 6, 2019

Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

AUROBINDO PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of AUROBINDO PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

More Views on News

Most Popular

Sorry Warren Buffett, I'm Following This Man Instead of You in 2020(The 5 Minute Wrapup)

Mar 30, 2020

This man warned of an impending market correction while everyone else was celebrating the renewed optimism in early 2020...

One Stock that is All Charged Up for the Post Coronavirus Rebound(The 5 Minute Wrapup)

Apr 1, 2020

A stock with strong moat is currently trading near 5-year lows.

A Safe Stock to Lockdown Now(The 5 Minute Wrapup)

Apr 2, 2020

The market crashc has made strong, established brands attractive. Here's a stock to make the most of this opportunity...

The Insiders See a Buying Opportunity in These Smallcaps Amid Coronavirus Outbreak(Profit Hunter)

Mar 31, 2020

The promoters are buying these smallcaps amid the coronavirus outbreak.

How to Identify a Market Rebound(Fast Profits Daily)

Mar 27, 2020

This very useful indicator can spot a market bottom.

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Apr 8, 2020 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS